Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 12 November 1996.
A single-dose rising study and a two-week, multiple-dose escalation study, which involved a total of 27 HIV-positive patients, have been completed. Results indicate that Zintevir(TM), administered at doses up to 6 mg/kg, is extremely well tolerated. No clinically significant adverse events were reported. Results also indicate that Zintevir(TM) plasma concentrations exceeded in vitro inhibitory concentration for the HIV virus for periods of up to 10 hours following administration of the higher doses. These results provide valuable information for the further development of this novel compound as a potential therapeutic for treating HIV infection.
"Inhibition of integrase, one of the key steps in the life cycle of the HIV virus, may provide another means of inhibiting viral replication and may complement the currently available therapeutic approaches of inhibiting reverse transcriptase and protease," according to James M. Chubb, Ph.D. President of Aronex. "The planned follow-on study with Zintevir(TM) will explore several multiple dosage regimens designed to optimize activity, as measured by effects on viral load and CD4 counts."
Zintevir(TM) belongs to a class of novel oligonucleotides discovered by Aronex scientists. Preclinical studies have indicated that Zintevir(TM) inhibits the integrase enzyme, one of the key steps in the life cycle of the HIV virus. Preclinical studies have also shown that Zintevir(TM) is a very stable molecule widely distributed throughout the body, and that tissue concentrations of the drug are maintained for periods exceeding five days following single doses.
Aronex Pharmaceuticals, Inc. is a leading biopharmaceutical company engaged in the discovery and development of proprietary innovative medicines to treat cancer and life-threatening infectious diseases. Aronex currently has four products (Nyotran(TM), Atragen(TM) (TretinoinLF), Annamycin and Zintevir(TM)) in various stages of ongoing clinical development and a number of products in preclinical development.
Any statements which are not historical facts contained in this release are forward looking statements that involve risks and uncertainties, including but not limited to those relating to product demand, pricing, market acceptance, the effect of economic conditions, intellectual property rights and litigation and the outcome of governmental proceedings, competitive products, risks in product and technology development, the results of financing efforts, the ability to complete transactions and other risks identified in the Company's Securities and Exchange Commission filings.
CONTACT: Connie Stout, Manager, Corporate Communications of Aronex Pharmaceuticals, Inc., 281-367-1666 or http://www.Aronex.com, or Janna Guinen Account Executive of Feinstein Partners Inc., 617-577-8110 or janna_guinen@fpinc.com or http://www.fpinc.com/ 06:59 EST
Copyright (c) 1996/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
961112
PR961111
Copyright © 1996 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .